Navigation Links
Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors

IRVINE, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products used in the treatment of patients suffering from severe angina, today announced the addition of veteran medical device executive and an experienced public company director, Raymond W. Cohen as a member of the Company's Board of Directors, increasing the number of board members to six.

Mr. Cohen, 49, has over 25 years of executive experience in the medical technology field and is currently the Chief Executive Officer and a member of the Board of Directors of Symphony Medical Inc., a venture-capital backed developer of novel biotherapeutic therapies to treat heart failure and other cardiac abnormalities.

For the decade prior to 2006, Cohen served as Chairman and CEO of publicly traded Cardiac Science, Inc. having served in that role during the period of rapid revenue growth and through the company's merger with Quinton Cardiology in late 2005. Today Cardiac Science is a leading manufacturer of automated public-access defibrillators and diagnostic cardiology systems, generating over $200 million in annual revenue. Cohen continues to serve on the board of Cardiac Science and also serves on the boards of BioLife Solutions, Inc., a publicly traded company, and BioGenex, Inc., and Syncroness, Inc.

Paul J. McCormick, the Company's Chairman of the Board commented, "Mr. Cohen has a solid track record of success in developing and commercializing innovative medical technology, particularly in the cardiovascular market. He brings the vision, insight and skills necessary to make a significant contribution to the Cardiogenesis Board of Directors and our shareholders. We are very pleased to have Mr. Cohen join our board and look forward to working with him."

About Cardiogenesis Corporation

Cardiogenesis specializes in providing surgical devices to treat cardiovascular disease and severe angina. The Company's market leading holmium:YAG laser system and single use fiber-optic delivery systems are used to perform a procedure known as Transmyocardial Revascularization (TMR). To date, thousands of patients have been treated with the Cardiogenesis TMR technology.

For more information on Cardiogenesis, please visit the Company's website at Cardiogenesis also maintains a website where patients suffering from angina can learn more about the TMR procedure at

SafeHarbor Statement

With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the possible effectiveness of the Company's technologies and the effect of such technologies on the Company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and the Company's other recent SEC filings. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE Cardiogenesis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cardiogenesis Reports Third Quarter 2008 Results
2. Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results
3. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
4. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
5. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
6. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
7. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
8. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
9. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
10. Genoptix Announces Participation at the Twentieth Annual Piper Jaffray Healthcare Conference
11. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Post Your Comments:
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... 25, 2015 , ... Jessica Richman and Zachary Apte, founders ... initial angel funding process. Now, they are paying it forward to other microbiome ... investments in the microbiome space. In this, they join other successful entrepreneurs-turned-angels ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
Breaking Biology Technology:
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
(Date:10/23/2015)... and GOLETA, California , ... HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce a ... eye tracking data captured during interactive real-world tasks ... and play integration of their established wearable solutions for ... to synchronize gaze behavior captured with SMI Eye ...
(Date:10/22/2015)... SAN JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ... results for its first quarter ended September 30, 2015. ... first quarter of fiscal 2016 grew 66 percent over the comparable ... quarter of fiscal 2016 was $23.8 million, or $0.62 per diluted ... net income for the first quarter of fiscal 2016 grew 39 ...
Breaking Biology News(10 mins):